



Tufts Center for the Study of Drug Development

TUFTS UNIVERSITY

# Impact REPORT

ANALYSIS AND INSIGHT INTO CRITICAL DRUG DEVELOPMENT ISSUES

## Clinical success rates for new cancer drugs double while more enter testing

*Success rates rose from 9.9% in the mid-1990s to 19.8% in the early-2000s*

- The number of new cancer drugs entering clinical testing increased 50% between 1993-98 and 1999-04.
- The clinical success rate for new cancer drugs entering clinical testing across the 12-year period of 1993-04 was 13%.
- 72% of new, investigational cancer compounds focused solely on solid tumor indications, whereas 20% were studied in both solid tumor and hematological indications.
- Small molecule drugs had higher success rates than biologics in transitioning from Phase I to Phase II and from Phase II to Phase III.
- Drugs focused solely on hematologic tumors had a 36% success rate over the 1993-04 period, compared to 10% for drugs focused only on solid tumors.